Multicenter, phase II study of chemotherapy with dose-dense modified TCF in locally advanced or metastatic gastric cancer. - ND

GRUPPO ONCOLOGICO ITALIANO DI RICERCA0 个研究点开始时间: 2008年2月13日最近更新: 2012年8月28日

适应症

试验速览

暂无简介。

•Age > 18 years. Istologically confirmed gastric adenocarcinoma. Unresectable stage III or stage IV disease. Measurable or evaluable disease.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•ECOG PS ≥ 2. Previous chemotherapy for advanced disease. Adjuvant treatments are allowed if ended at least 6 months before. Adequate hepatic, renal and hematological functions. History of another malignancy within the past five years except basal cell carcinoma of the skin or carcinoma in situ of the cervix. Patients who are:pregnant or lactating;at risk of pregnancy during the study. This must be checked by pregnancy test at study entry. The patient must be receiving a medically accepted contracceptive regimen. Absence of any psychological, familial, sociological or geographical conditions potentially hampering compliance with the study protocol and follow-up schedule. Refusal to give and sign informed consent.

发起方

GRUPPO ONCOLOGICO ITALIANO DI RICERCA